A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2002
12/19/2002	WO2002100847A2 Factor xa inhibitor
12/19/2002	WO2002100833A1 Rho KINASE INHIBITORS
12/19/2002	WO2002100830A1 Pyrrolidine derivatives as factor xa inhibitors
12/19/2002	WO2002100825A2 Anthranilic acid amides with a heteroarylsulfonyl side chain, and use thereof as antiarrhythmic active substances
12/19/2002	WO2002100813A2 Modulators of peroxisome proliferator activated receptors
12/19/2002	WO2002100812A1 Carboxylic acid derivative and salt thereof
12/19/2002	WO2002100486A1 Method and apparatus for treating uterine myoma
12/19/2002	WO2002100456A1 Using supercritical fluids to infuse therapeutic on a medical device
12/19/2002	WO2002100445A1 Treatment and composition for wound healing
12/19/2002	WO2002100422A1 Pharmaceutical formulation consisting of a plant dry extract with a calcium coating
12/19/2002	WO2002100419A1 Use of a phosphate adsorbent to combat vascular diseases
12/19/2002	WO2002100412A2 Stabilized dispersion of phytosterol in oil
12/19/2002	WO2002100411A1 Naphtothiazine positive allosteric ampa receptor modulators (paarm)
12/19/2002	WO2002100410A1 Methods of treating alzheimer's disease
12/19/2002	WO2002100408A2 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels
12/19/2002	WO2002100405A1 Isoquinoline inhibitors of p38
12/19/2002	WO2002100403A1 Modulators of peroxisome proliferator activated receptors (ppar)
12/19/2002	WO2002100400A1 Organic nitrate-based compounds for the treatment of vasculopathies
12/19/2002	WO2002100399A1 Macrocycles useful in the treatment of alzheimer's disease
12/19/2002	WO2002100390A2 Improved method of treating the syndrome of coronary heart disease risk factors in humans
12/19/2002	WO2002100386A1 Controlled heat induced rapid delivery of pharmaceuticals from skin depot
12/19/2002	WO2002100341A2 Compounds for the treatment of metabolic disorders
12/19/2002	WO2002100336A2 Tissue-specific endothelial membrane proteins
12/19/2002	WO2002100332A2 Isoxazoline compounds having mif antagonist activity
12/19/2002	WO2002100330A2 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES
12/19/2002	WO2002100328A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	WO2002100327A2 Substituted 1-benzazepines and derivatives thereof
12/19/2002	WO2002100323A2 METHYL ANALOGS OF SIMVASTATIN AS NOVEL HMG-CoA REDUCTASE INHIBITORS
12/19/2002	WO2002087604A3 Preparations containing a combination of vitamin e and afamin
12/19/2002	WO2002087583A3 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
12/19/2002	WO2002085906A3 Phthalazinones derivatives useful as pde4/7 inhibitors
12/19/2002	WO2002078684A3 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
12/19/2002	WO2002076405A3 Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
12/19/2002	WO2002070565A3 High-affinity antagonists of elr-cxc chemokines
12/19/2002	WO2002070561A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070560A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070558A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070515A3 Chromane derivatives, process for their preparation and their use as antitumor agents
12/19/2002	WO2002069972A3 Triazole compounds and the use thereof in the prophylaxis and therapy of neurodegenerative diseases, cerebral trauma and cerebral ischemia
12/19/2002	WO2002069899A3 Methods and compositions for the treatment and prevention of smooth muscle cell proliferation
12/19/2002	WO2002064755A3 Post-partum mammalian placenta, its use and placental stem cells therefrom
12/19/2002	WO2002060894A3 Sulfonamide lactam inhibitors of factor xa
12/19/2002	WO2002059080A3 Trisubstituted carbocyclic cyclophilin binding compounds and their use
12/19/2002	WO2002058626A9 Methods and compositions for the identification and treatment of neurodegenerative disorders
12/19/2002	WO2002057222A3 Thiol-based naaladase inhibitors
12/19/2002	WO2002055501A3 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
12/19/2002	WO2002005795A3 Pharmaceutical combinations for treatment and prevention of diabetes mellitus
12/19/2002	WO2001077169A9 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
12/19/2002	WO2001068859A9 Il-17 receptor like molecules and uses thereof
12/19/2002	WO2001047919A9 Substituted oxazolidinones and their use in the field of blood coagulation
12/19/2002	WO2000058303A9 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
12/19/2002	US20020194633 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
12/19/2002	US20020193614 Treatment of cardiovascular disorders
12/19/2002	US20020193612 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
12/19/2002	US20020193605 Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease
12/19/2002	US20020193589 Mercaptoacetylamide derivatives, a process for their preparation and their use
12/19/2002	US20020193571 Wsx receptor agonist antibodies
12/19/2002	US20020193562 Angiotensin converting enzyme (ACE); neutral endopeptidase (NEP); containing a dipeptide derived from an amino acid, or a conformationally restricted dipeptide mimic
12/19/2002	US20020193561 P53 protein variants and therapeutic uses thereof
12/19/2002	US20020193446 Compounds and methods for the inhibition of the expression of VCAM-1
12/19/2002	US20020193439 90-95% eicosapentaenoic acid (EPA) and < 5% of docosahexaenoic acid (DHA); treating psychiatric or central nervous disorders
12/19/2002	US20020193432 Useful as modulators of the interaction between the receptor for advanced glycated end product and its ligands
12/19/2002	US20020193431 Administration of an effective amount of 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4, Lipoxin-A4, 15-epi-lipoxin4 or 15-R/S-methyl-lipoxin4 or salts, esters, amides, carboxylic acids or prodrugs to treat angiogenesis
12/19/2002	US20020193422 Anthranilamides and methods of their use
12/19/2002	US20020193410 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans
12/19/2002	US20020193409 Prodrugs of anticancer agents employing substituted aromatic acids
12/19/2002	US20020193405 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases
12/19/2002	US20020193403 Administering retinoic acid receptors (RAR) antagonist or an RAR inverse agonist for therapy of hyperlipidemia in mammal
12/19/2002	US20020193381 For preventing contractions of the urethra and lower urinary tract, without substantially affecting blood pressure; for blocking alpha 1 receptors
12/19/2002	US20020193377 Quinazolines as MMP-13 inhibitors
12/19/2002	US20020193360 For enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease (AD), mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease
12/19/2002	US20020193357 Liver X receptor agonists
12/19/2002	US20020193348 As blood-coagulation inhibitor or an agent for therapy and prophylaxis of thrombosis or embolism, containing
12/19/2002	US20020193327 For therapy of eye disorders including retinitis pigmentosa, Stargardt's disease, diabetic retinopathies, retinal vascularization, or retinoblastoma
12/19/2002	US20020193317 Using smilagenin, prazerigenin, an astragaloside, tigogenin, ruscogenin, hecogenin and diosgenin in manufacture of medicament for therayp of condition characterised by deficiency in postsynaptic membrane-bound receptor number
12/19/2002	US20020193307 Antagonism of endothelin actions
12/19/2002	US20020193302 Use of FVIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
12/19/2002	US20020193288 Methods of treating hypertension and compositions for use therein
12/19/2002	US20020192800 Nucleotide sequences coding polypeptide for use in the prevention, diagnosis and treatment of thrombosis, emphysema and liver disorders
12/19/2002	US20020192794 Purification of plasmin; obtain sample of plasminogen, incubate with activator, recover plasmin
12/19/2002	US20020192760 Nucleotide sequences coding membrane protein for use the diagnosis and treatment of asthma, parkinson's, heart defects, hypotension, urogenital disorders
12/19/2002	US20020192758 C3b/C4b complement receptor-like molecules and uses thereof
12/19/2002	US20020192749 Human polynucleotides, polypeptides, and antibodies
12/19/2002	US20020192737 Detecting modulators of oxidoreductases; obtain sample, incubate with modulator, detect signal, monitor adjustment in enzyme activity
12/19/2002	US20020192682 Polynucleotides and polypeptides of the IFNalpha-2 gene
12/19/2002	US20020192643 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferation or inflammatory disorders
12/19/2002	US20020192317 Preventive, alleviative or remedy for hypertension
12/19/2002	US20020192285 Controlled release pellet formulation
12/19/2002	US20020192203 Sterol absorption inhibitor compositions
12/19/2002	US20020192157 Treatment and diagnosis of macrophage mediated disease
12/19/2002	DE10128511A1 Treating or preventing atherosclerosis and/or bone metabolism disorders, especially in dialysis patients, using polynuclear metal oxide-modified adsorption material
12/19/2002	DE10128331A1 New 2-(heteroarylsulfonyl-amino)-benzamide derivatives, which are potassium ion channel blocking antiarrhythmic agents, useful for e.g. treating atrial fibrillation or flutter
12/19/2002	DE10127897A1 Combined pharmaceutical formulation for treating osteoporosis or related disorders, comprising core of dried plant extract enclosed in sheath of calcium salt
12/19/2002	DE10121003A1 Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen Anthranilic acid amides, processes for preparing, their use as a medicament as well as pharmaceutical compositions containing them
12/19/2002	CA2450617A1 Methyl analogs of simvastatin as novel hmg-coa reductase inhibitors
12/19/2002	CA2450366A1 Controlled heat induced rapid delivery of pharmaceuticals from skin depot
12/19/2002	CA2450240A1 Treatment and composition for wound healing
12/19/2002	CA2450167A1 Macrocycles useful in the treatment of alzheimer's disease
12/19/2002	CA2450027A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449948A1 Methods of treating alzheimer's disease

1 ... 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 ... 1595